Navigation Links
Presence of substandard drugs can pose concern for patients,,

German scientists have found out that the drug streptokinase used in many non-European countries //are not up to the standard, as the amount of streptokinase present in the preparation is really low.

The study, which had tested 16 different forms of streptokinase medications across the European continent, has found only three formulations that match the safety and quality standards.

The drug streptokinase is used for its anti-clotting effect and if administered after a cardiac arrest, it can increase the chances of survival by over 25%.

The study showed that medications could only realize the claims that had been made in their labels by as high as 90% to as low as 20% in some cases. These drugs are sold in countries like Brazil, India, Jordan, China and Pakistan. The report which comes out in the latest issue of the journal Circulation has once again raised the question of substandard drugs being marketed at countries where the healthcare industry is not so stringent on the quality of the medications marketed.

Researchers are of the opinion that the cases of counterfeit medications are high in the countries where the disease incidence is high and the public monitoring system is under pressure. However it still remains important that our country takes additional steps to monitor the problem of counterfeit drugs.
'"/>




Page: 1

Related medicine news :

1. Tamoxifen Ineffective In Presence Of Genetic Variation in Breast Cancer
2. Haj Pilgrims Being Tested For Presence Of Bird Flu Infection
3. Presence Of Live Avian Flu Is A Cause Of Concern: Scientists
4. Hormone Can Foretell Presence Of Potentially Fatal Pulmonary Hypertension
5. Breath to Reveal Presence of Breast Cancer
6. Presence of Beneficial Bacteria in Probiotic Drinks Mere Tall Claims
7. Presence of Pesticides and Metals in Fruits and Vegetable
8. Cancer drugs in development nearly doubled since 1995
9. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
10. African HIV strains more resistant to anti HIV drugs
11. Right drugs drastically cut stroke risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: